Franklin Resources Inc. raised its position in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,337,569 shares of the company’s stock after buying an additional 200,310 shares during the quarter. Franklin Resources Inc. owned about 0.07% of Karyopharm Therapeutics worth $32,041,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the business. State Street Corp lifted its position in Karyopharm Therapeutics by 10.1% during the second quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after buying an additional 47,127 shares during the period. Northern Trust Corp lifted its position in Karyopharm Therapeutics by 36.5% during the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock valued at $3,668,000 after buying an additional 108,369 shares during the period. Iguana Healthcare Management LLC lifted its position in Karyopharm Therapeutics by 33.3% during the third quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $4,392,000 after buying an additional 100,000 shares during the period. Dimensional Fund Advisors LP lifted its position in Karyopharm Therapeutics by 17.3% during the second quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock valued at $2,930,000 after buying an additional 47,699 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Karyopharm Therapeutics by 753.5% during the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after buying an additional 271,208 shares during the period. 62.60% of the stock is owned by institutional investors and hedge funds.
In other Karyopharm Therapeutics news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $15.29, for a total value of $152,900.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares of the company’s stock, valued at approximately $7,983,566.47. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Christopher Brett Primiano sold 2,500 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $16.03, for a total value of $40,075.00. Following the completion of the transaction, the executive vice president now directly owns 4,881 shares of the company’s stock, valued at approximately $78,242.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,000 shares of company stock valued at $928,625. 14.71% of the stock is owned by insiders.
KPTI stock opened at $15.66 on Wednesday. Karyopharm Therapeutics Inc has a 52-week low of $7.48 and a 52-week high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $2.26 million. Karyopharm Therapeutics had a negative return on equity of 89.62% and a negative net margin of 67,267.47%. Karyopharm Therapeutics’s revenue for the quarter was up 3163.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.65) EPS. analysts predict that Karyopharm Therapeutics Inc will post -2.72 EPS for the current fiscal year.
KPTI has been the subject of several recent research reports. HC Wainwright raised their price objective on Karyopharm Therapeutics to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 15th. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 15th. Canaccord Genuity lifted their price target on Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, March 12th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, March 2nd. Finally, BidaskClub raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 9th. Two analysts have rated the stock with a sell rating and ten have assigned a buy rating to the stock. Karyopharm Therapeutics currently has an average rating of “Buy” and a consensus price target of $19.60.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/21/franklin-resources-inc-purchases-200310-shares-of-karyopharm-therapeutics-inc-kpti.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.